Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study

Determine whether specific CTNNB1 or APC mutations in patients with desmoid tumor were associated with differences in clinical responses to systemic treatments. We established a multi-institutional dataset of previously treated patients with desmoid tumor across four U.S. sarcoma centers, including...

Full description

Bibliographic Details

Published in:	Clinical cancer research Vol. 28; no. 18; pp. 4092 - 4104
Main Authors:	Nathenson, Michael J, Hu, Junxiao, Ratan, Ravin, Somaiah, Neeta, Hsu, Robert, DeMaria, Peter J, Catoe, Heath W, Pang, Angela, Subhawong, Ty K, Amini, Behrang, Sweet, Kevin, Feister, Katharina, Malik, Karan, Jagannathan, Jyothi, Braschi-Amirfarzan, Marta, Sheren, Jamie, Caldas, Yupanqui, Moreno Tellez, Cristiam, Rosenberg, Andrew E, Lazar, Alexander J, Maki, Robert G, Benedetto, Pasquale, Cohen, Jonathan, Trent, Jonathan C, Ravi, Vinod, Patel, Shreyaskumar, Wilky, Breelyn A
Format:	Journal Article
Language:	English
Published:	United States American Association for Cancer Research 15-09-2022
Subjects:	beta Catenin - genetics Fibromatosis, Aggressive - drug therapy Fibromatosis, Aggressive - genetics Fibromatosis, Aggressive - pathology High-Throughput Nucleotide Sequencing Humans Mutation Prognosis Retrospective Studies Translational Cancer Mechanisms and Therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!